What EvE Bio does

EvE Bio is a non-profit Focused Research Organization (FRO) founded in 2023 in Durham, North Carolina, operating under Convergent Research with philanthropic support from Schmidt Futures, Founders Pledge, and Lyda Hill Philanthropies. The company systematically maps the pharmome by profiling libraries of small-molecule drugs against hundreds of druggable human proteins — nuclear receptors, 7-transmembrane receptors, and kinases — using a proprietary two-phase quantitative high-throughput screening process: a 3-concentration primary screen followed by 11-point concentration-response profiling with four-parameter logistic curve fitting. As of June 2026 (Data Release #12), the dataset comprises 648,208 rigorously confirmed drug-target interactions across 256 validated targets and 1,397 compounds, described as the largest public resource of its kind.

The core product is the Pharmome Mapping Dataset, distributed through four channels: a free interactive Data Explorer web app, downloadable data packages, programmatic access on Hugging Face, and integration into DrugBank's commercial drug discovery intelligence platform (where DrugBank also serves as commercial sponsor). The dataset is offered under a Creative Commons CC BY-NC-SA 4.0 license for non-commercial use, with alternative commercial licensing available on direct inquiry. Customer segments span pharmaceutical and biotech researchers (off-target liability assessment, drug repurposing), AI/ML researchers in drug discovery (training and validation data for models such as FutureHouse's ether0), academic researchers, and disease-specific AI initiatives (notably OpenAI Foundation's AI for Alzheimer's program on allosteric modulators). Revenue is generated primarily through philanthropic grants and a single named commercial sponsor rather than transactional software sales.

Name

EvE Bio

Legal name

EvE Bio, LLC

Website

https://evebio.org

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

11–50 employees

Short description

EvE Bio is a non-profit Focused Research Organization that systematically maps drug-target interactions across hundreds of human proteins, producing the largest public pharmome-mapping dataset for pharma researchers, AI/ML drug-discovery teams, and academic users.

Ownership category

akta.pro rank

Product category

Drug Discovery Data and Analytics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Medical Laboratories (621511)

SIC

Services-Medical Laboratories (8071), Services-Prepackaged Software (7372)

akta.pro primary industry

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

akta.pro secondary industries

Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI), Bioinformatics & Multi-omics Analysis Software (HLAGAJAD), Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries) (HLAAAIAL)

Keywords

• Pharmome mapping datasets
• Drug target interaction data
• High throughput screening
• Pharmacology research data
• Drug discovery intelligence

Headquarters

HQ city

Durham

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Supply Chain, Infrastructure, Marketing or Sales

Revenue model

1. Public Data Access (Non-profit / Open Science): EvE Bio is a non-profit Focused Research Organization (FRO). Primary outputs are freely available under Creative Commons CC BY-NC-SA 4.0 license. Funded by philanthropic support from Convergent Research, Eric and Wendy Schmidt/Schmidt Futures, Founders Pledge, and Lyda Hill Philanthropies.
2. Commercial Data Licensing: Alternative licensing options including commercial terms are available by contacting [email protected]. The data is also integrated into DrugBank's commercial platform, with DrugBank acknowledged as EvE's commercial sponsor.
3. Partnership Integration Revenue: Integration with commercial platforms (DrugBank) likely generates revenue through co-distribution arrangements. DrugBank is listed as a commercial sponsor.

Pricing tiers

Go-to-market motion1 record

Distribution channels5 records

Marketing channels10 records

Core offering

EvE Bio generates a systematic pharmome-mapping dataset by quantitatively screening drug libraries across hundreds of druggable human proteins. It makes the resulting drug-target interaction data available through an interactive Data Explorer, downloadable files, and a Hugging Face dataset, with commercial licensing available by direct inquiry.

Product overview

EvE Bio is a Focused Research Organization that produces the world's largest pharmome-mapping dataset—a comprehensive collection of drug-target interaction data. The core offering is the Pharmome Mapping Dataset containing 648,208 interactions across 256 targets and 1,397 compounds. This data is made accessible through multiple channels: the interactive EvE Bio Data Explorer web application for visual exploration and analysis, downloadable Data Packages for offline use, and the Hugging Face Dataset for programmatic ML access. The company generates data in-house at its North Carolina laboratory using quantitative high-throughput screening with two phases (3-point screening followed by 11-point profiling), providing rigorous confirmation of inactive compounds and quantified potency for active compounds. Key applications enabled by the dataset include off-target liability assessment, drug repurposing identification, and training/validation data for AI and machine learning models in drug discovery.

Differentiator

Problem solved

Functional benefit

Products and services

• Pharmome Mapping Dataset A structured dataset of drug-target activity covering 1,397 compounds and 256 screened targets, including nuclear receptors, 7TM receptors, and kinases. As of Data Release #12, it contains 648,208 screened interactions and records a result for every compound-target combination.
• EvE Bio Data Explorer An interactive web application that lets researchers explore pharmome-mapping results, visualize dose-response curves, and filter by target class, target, compound, mode, mechanism, and assay.
• Data Downloads Downloadable summary results, computational results, compound and target metadata, assay metadata, observed data points, and methods documentation for offline analysis. Public files are offered under the Creative Commons CC BY-NC-SA 4.0 license.

Named customers1 record

Segments4 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability4 records

Feature5 records

Partnerships

Four partnerships are on record, tiered core and flagship.

• OpenAI FoundationcoreStrategic or Co-development Partner · 8 April 2026EvE Bio partnered with OpenAI Foundation on their 'AI for Alzheimer's' initiative. EvE will produce focused pharmacology datasets needed for AI models to learn allosteric modulator design, with dozens of Alzheimer's-relevant targets in their existing repertoire. The partnership aims to address the data gap that makes designing allosteric modulators difficult for AI models.
• DrugBankcoreStrategic or Co-development Partner · 18 November 2025EvE Bio and DrugBank partnered to integrate EvE's pharmome-mapping dataset — 385,572 rigorously confirmed drug-target interactions across 1,397 compounds and 159 validated targets — into DrugBank's drug discovery intelligence platform. This integration enables applications such as off-target liability assessment, drug repurposing, and enriched cheminformatics analysis. DrugBank is also acknowledged as EvE's commercial sponsor.
• Hugging FacecoreTechnology or Integration · 18 November 2025EvE Bio's pharmome dataset is accessible programmatically on Hugging Face via the python datasets library, enabling ML researchers to integrate the data directly into their machine learning workflows. The integration was highlighted as making the data accessible to researchers in an actionable format.
• FutureHouseflagshipStrategic or Co-development Partner · 18 November 2025FutureHouse used EvE Bio's data for training and validation of ether0, their chemistry-specific reasoning model. Their work demonstrated that domain-specific AI development can be surprisingly data efficient, validating EvE's vision of providing experimental ground truth for AI model development.

Scale indicators9 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Insitro: Insitro is an AI/ML-driven drug discovery company that combines high-throughput biology with machine learning models to predict drug behavior. It shares EvE Bio's philosophy of using systematic experimental data to train AI for pharma, but operates as a for-profit therapeutics company.
• Recursion Pharmaceuticals: Recursion is an AI-driven drug discovery company that combines high-throughput wet-lab biology with machine learning. While it pursues internal therapeutic programs rather than open data, its scale of experimental data generation and use of ML to drive drug discovery makes it a broader incumbent comparable to EvE's approach.
• Isomorphic Labs: Isomorphic Labs (Alphabet-owned) applies DeepMind's AI to drug discovery, with significant investment in proprietary drug-target interaction data and modeling. It represents a much larger, well-capitalized player working on the same problem EvE addresses—generating systematic molecular interaction data for AI-driven drug design.

Direct peers

• DrugBank: DrugBank is a leading drug knowledge platform providing pharmaceutical and pharmacological data on drugs, targets, and pathways. It is both EvE Bio's primary commercial sponsor and distribution partner, integrating EvE's dataset into its enterprise platform—the most directly comparable company by product overlap and customer base.
• ChEMBL: ChEMBL is a manually curated database of bioactive molecules with drug-like properties, maintained by EMBL-EBI. It is one of the largest public resources for drug-target bioactivity data, directly comparable to EvE's pharmome-mapping dataset in scope, public availability, and use cases.
• PharmGKB: PharmGKB is a pharmacogenomics knowledge resource that collects, encodes, and disseminates knowledge about the impact of human genetic variation on drug response. While more focused on clinical pharmacogenomics, it shares EvE Bio's mission of building public, structured pharmacology data for the research community.
• PubChem: PubChem is the NIH's open chemistry database aggregating chemical structures, bioactivity assay results, and target information. Like EvE, it serves as a foundational public data resource for drug discovery and cheminformatics research.
• Open Targets: Open Targets is a public-private partnership that builds systematic target identification and validation datasets for drug discovery. Like EvE Bio, it generates open-access, structured experimental data to support target prioritization, making it a direct peer in the open target-identification data space.

Emerging players

• Atomwise: Atomwise applies AI to predict drug-target binding using structure-based models and has historically partnered with academic groups to generate experimental binding data. It overlaps with EvE Bio's mission of using ML for drug discovery but historically focused more on binding prediction than systematic experimental profiling.

Others

• Convergent Research: Convergent Research is EvE Bio's parent organization—the Focused Research Organization (FRO) that incubates and funds ambitious, time-limited scientific projects like EvE. While not a direct competitor, it is the structural and funding peer that defines EvE's operating model and connects it to similar FROs in adjacent scientific domains.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/EvEBiotech
• LinkedInlinkedin.com/company/eve-bio

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about EvE Bio